Komodo Health is a healthcare technology company creating the new standard for real-world data and analytics through its platform, which enables real-time, accurate, and actionable insight into the treatment, diagnosis, costs, and outcomes journeys of millions of patients across the US. Find out more at https://www.komodohealth.com/

Readout AI turns clinical trial data into insights, automatically. The AI applies appropriate biostatics to raw data, and then describes the findings in paragraphs for clinical study reports, abstracts or even posters. Readout AI turbocharges medical writing and biostatistics, shrinking the time to turn raw clinical data into actionable outputs. For more information, visit: https://readout.ai/

Unlearn is a pioneering AI company with a product-driven focus, dedicated to transforming medicine by eliminating trial and error. Our Platform harnesses the power of digital twins—advanced computational models of patients—to empower pharmaceutical and biotech companies to overcome critical challenges in clinical development. For more information, go to https://www.unlearn.ai/

Evidation connects directly with millions of individuals to measure, understand, and improve health in everyday life so that everyday health insights can become extraordinary innovations. Evidation helps customers harness longitudinal real-world data, so they can accelerate recruitment, enhance medical evidence and more successfully engage and activate patients. To learn more, visit https://evidation.com/

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. To learn more, please visit www.astrazeneca.com

Altus is focused on developing value-added medicines in the central nervous system (CNS) space. We leverage a range of patented drug delivery technologies to formulate cost-effective and quick-to-market solutions designed to address unmet patient needs in growing therapeutic areas. We’re seeking co-development partners for in-licensing opportunities across the globe. To learn more, please visit www.altusformulation.com

Nothing is easy when it comes to developing and manufacturing drug delivery systems. But our extensive knowledge, steadfast spirit, and inventive character mean we have navigated endless challenges to bring a wealth of firsts, innovations, and successes to pharmaceutical and biotech drug-delivery initiatives. Kindeva’s MTS platform provides elegant microneedle-based delivery devices, refined and suited to our partners’ programs. From early-phase feasibility to final design requirements, we can meet the needs of challenging drug formulations. Refined over several device generations, Kindeva’s microstructured systems are designed for consistent intradermal delivery of vaccines and biologics. Our patient-friendly technology is available in two formats, providing an option of delivery routes to enable your commercial success. With sophisticated project management, rigorous quality processes, manufacturing excellence, and cGMP facilities, Kindeva supports a reliable supply chain for your program. To learn more, visit https://kindevadd.com/

We are a leader in next-generation vaccine and biologics delivery technology. With one core platform, we have multiple drug delivery devices for HCP and self-administration. Pharma Latch Hollow is an innovative solution that utilises hollow microneedles for direct intradermal administration delivered by HCP’s. The technology creates a new injection usability paradigm that is highly cost effective and scalable. For more information visit: www.pharmalatch.com

TEST

Re-Vana Therapeutics is a Transformative Ocular Therapeutics company, developing Sustained Release 6 Months+ Biologics with our proprietary biodegradable photo crosslinked technologies. To learn more, please visit https://www.revanatx.com/

SynerGene seeks to improve patient outcomes through novel nanomedicines that enhance the delivery of therapeutic molecules via a nanocomplex that not only “homes” to cancer cells but also delivers diverse payloads across the blood-brain barrier. SynerGene’s SGT-53 is now in a Phase II trial for patients with advanced pancreatic cancers. For more information visit synergeneapi.com